Live
Stempeutics has inked an out-licensing deal with Cipla, for its stem cell therapy product Stempeucel. It is suggested for treating critical limb ischemia.
In a statement the company stated, “Under this agreement, Cipla will get exclusive marketing rights for five years in India for critical limb ischemia due to atherosclerotic peripheral arterial disease (CLI-PAD) with Stempeutics manufacturing and supplying the product to Cipla.”
Further the company stated that, the product is expected to be available in the Indian market in the beginning of 2020, after undergoing the phase 3 clinical trail in India, which is expected to start in 2018.
